Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
Drug Resistance Updates · 2025-09 · 82 · 101266
DOI: 10.1016/j.drup.2025.101266 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Resistance Updates, 2025-09. Verfasst von Zhenfang Du und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics and Developmental Biology, School of Medicine, Southeast University, Nanjing, Jiangsu 210003, China. Electronic address: duzhe…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Lung Neoplasms. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 288 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China, Research Foundation of the Nanjing University of Chinese Medicine.
Abstract (Originalsprache)
Tyrosine kinase inhibitors (TKIs) have revolutionized the management of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Despite the initially favorable outcomes, these patients inevitably acquire resistance to EGFR-TKIs. The molecular mechanism of the acquired resistance is highly complex and heterogeneous, and can be generalized as three categories, including EGFR pathway reactivation (re-engagement of EGFR downstream), EGFR pathway bypass (adoption of a parallel pathway to re-engage the downstream transcriptional oncogenic output of the original EGFR), and EGFR pathway indifference (acquirement of a cellular state alternate to the original EGFR-driven output). This review summarizes the recent progress on the identification and understanding of the acquired resistance mechanisms to EGFR-TKIs in patients with NSCLC. The potential strategies to delay or overcome the acquired resistance are also discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Genetics and Developmental Biology, School of Medicine, Southeast University, Nanjing, Jiangsu 210003, China. Electronic address: duzhenfang@seu.edu.cn.
- School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, China.
- Department of Genetics and Developmental Biology, School of Medicine, Southeast University, Nanjing, Jiangsu 210003, China; School of Life Science and Technology, Southeast University, Nanjing 210018, China.
- Department of Genetics and Developmental Biology, School of Medicine, Southeast University, Nanjing, Jiangsu 210003, China.
- Translational Research, Cancer Institute, Peking University Shenzhen Hospital, Shenzhen-Peking University-Hong Kong University of Science and Technology Medical Center, Shenzhen 518036, China.
- Department of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710048, China.
Förderung
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
- Research Foundation of the Nanjing University of Chinese Medicine
- Jiangsu-Specially Appointed Professors Program
- Southeast University
- Nanjing University of Chinese Medicine
- Scientific Research Foundation for Youth Scholars of Southease University
Zitieren
APA
Du, Z., Kan, H., Sun, J., Liu, Y., Gu, J., Akemujiang, S., Zou, Y., Jiang, L., Wang, Q., Li, C., Luo, L., Zhang, Y., Fan, H., Luo, P., & Wang, B. (2025). Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resistance Updates, 82, 101266. https://doi.org/10.1016/j.drup.2025.101266
Vancouver
Du Z, Kan H, Sun J, Liu Y, Gu J, Akemujiang S, et al. Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resistance Updates. 2025;82:101266. doi:10.1016/j.drup.2025.101266
BibTeX
@article{Du2025,
author = {Du, Zhenfang and Kan, Hongfei and Sun, Jinghan and Liu, Yue and Gu, Jiahui and Akemujiang, Shugela and Zou, Yudi and Jiang, Lufan and Wang, Qinzhuo and Li, Chen and Luo, Lei and Zhang, Yunkai and Fan, Hong and Luo, Pengfei and Wang, Bo},
title = {Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer},
journal = {Drug Resistance Updates},
year = {2025},
volume = {82},
pages = {101266},
doi = {10.1016/j.drup.2025.101266}
}
EUVIMED